Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Robert Breeze to Parkinson Disease

This is a "connection" page, showing publications Robert Breeze has written about Parkinson Disease.

 
Connection Strength
 
 
 
1.099
 
  1. Freed CR, Zhou W, Breeze RE. Dopamine cell transplantation for Parkinson's disease: the importance of controlled clinical trials. Neurotherapeutics. 2011 Oct; 8(4):549-61.
    View in: PubMed
    Score: 0.247
  2. Freed CR, Leehey MA, Zawada M, Bjugstad K, Thompson L, Breeze RE. Do patients with Parkinson's disease benefit from embryonic dopamine cell transplantation? J Neurol. 2003 Oct; 250 Suppl 3:III44-6.
    View in: PubMed
    Score: 0.142
  3. Breeze RE. Transplantation of embryonic dopaminergic neurons. Neurosurgery. 2001 Sep; 49(3):575-6.
    View in: PubMed
    Score: 0.123
  4. Breeze RE, Wells TH, Freed CR. Implantation of fetal tissue for the management of Parkinson's disease: a technical note. Neurosurgery. 1995 May; 36(5):1044-7; discussion 1047-8.
    View in: PubMed
    Score: 0.079
  5. Freed CR, Rosenberg NL, Schneck SA, Breeze RE. Improved drug responsiveness following fetal tissue implant for Parkinson's disease. Neurochem Int. 1992 Mar; 20 Suppl:321S-327S.
    View in: PubMed
    Score: 0.064
  6. Breeze RE. Implanting fetal tissue to treat Parkinson's disease. West J Med. 1990 Nov; 153(5):543-4.
    View in: PubMed
    Score: 0.058
  7. Ma Y, Tang C, Chaly T, Greene P, Breeze R, Fahn S, Freed C, Dhawan V, Eidelberg D. Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)F-FDOPA PET outcomes. J Nucl Med. 2010 Jan; 51(1):7-15.
    View in: PubMed
    Score: 0.054
  8. Freed CR, Breeze RE, Fahn S, Eidelberg D. Preoperative response to levodopa is the best predictor of transplant outcome. Ann Neurol. 2004 Jun; 55(6):896; author reply 896-7.
    View in: PubMed
    Score: 0.037
  9. Gordon PH, Yu Q, Qualls C, Winfield H, Dillon S, Greene PE, Fahn S, Breeze RE, Freed CR, Pullman SL. Reaction time and movement time after embryonic cell implantation in Parkinson disease. Arch Neurol. 2004 Jun; 61(6):858-61.
    View in: PubMed
    Score: 0.037
  10. Bj?rklund A, Dunnett SB, Brundin P, Stoessl AJ, Freed CR, Breeze RE, Levivier M, Peschanski M, Studer L, Barker R. Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol. 2003 Jul; 2(7):437-45.
    View in: PubMed
    Score: 0.035
  11. Trott CT, Fahn S, Greene P, Dillon S, Winfield H, Winfield L, Kao R, Eidelberg D, Freed CR, Breeze RE, Stern Y. Cognition following bilateral implants of embryonic dopamine neurons in PD: a double blind study. Neurology. 2003 Jun 24; 60(12):1938-43.
    View in: PubMed
    Score: 0.035
  12. Nakamura T, Dhawan V, Chaly T, Fukuda M, Ma Y, Breeze R, Greene P, Fahn S, Freed C, Eidelberg D. Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease. Ann Neurol. 2001 Aug; 50(2):181-7.
    View in: PubMed
    Score: 0.030
  13. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ, Eidelberg D, Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med. 2001 Mar 08; 344(10):710-9.
    View in: PubMed
    Score: 0.030
  14. Freed CR, Breeze RE, Fahn S. Placebo surgery in trials of therapy for Parkinson's disease. N Engl J Med. 2000 Feb 03; 342(5):353-4; author reply 354-5.
    View in: PubMed
    Score: 0.028
  15. Freed CR, Breeze RE, Schneck SA. Transplantation of fetal mesencephalic tissue in Parkinson's disease. N Engl J Med. 1995 Sep 14; 333(11):730-1.
    View in: PubMed
    Score: 0.020
  16. Ansari AA, Mayne A, Freed CR, Breeze RE, Schneck SA, O'Brien CF, Kriek EH, Zhang YB, Mazziotta JC, Hutchinson M, et al. Lack of a detectable systemic humoral/cellular allogeneic response in human and nonhuman primate recipients of embryonic mesencephalic allografts for the therapy of Parkinson's disease. Transplant Proc. 1995 Feb; 27(1):1401-5.
    View in: PubMed
    Score: 0.019
  17. Freed CR, Breeze RE, Rosenberg NL, Schneck SA. Embryonic dopamine cell implants as a treatment for the second phase of Parkinson's disease. Replacing failed nerve terminals. Adv Neurol. 1993; 60:721-8.
    View in: PubMed
    Score: 0.017
  18. Freed CR, Breeze RE, Rosenberg NL, Schneck SA, Kriek E, Qi JX, Lone T, Zhang YB, Snyder JA, Wells TH, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med. 1992 Nov 26; 327(22):1549-55.
    View in: PubMed
    Score: 0.017
  19. Freed CR, Breeze RE, Rosenberg NL, Schneck SA, Wells TH, Barrett JN, Grafton ST, Huang SC, Eidelberg D, Rottenberg DA. Transplantation of human fetal dopamine cells for Parkinson's disease. Results at 1 year. Arch Neurol. 1990 May; 47(5):505-12.
    View in: PubMed
    Score: 0.014
  20. Freed CR, Breeze RE, Rosenberg NL, Schneck SA, Wells TH, Barrett JN, Grafton ST, Mazziotta JC, Eidelberg D, Rottenberg DA. Therapeutic effects of human fetal dopamine cells transplanted in a patient with Parkinson's disease. Prog Brain Res. 1990; 82:715-21.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)